Reproductive System & Sexual Disorders: Current Research
Open Access
ISSN: 2161-038X
ISSN: 2161-038X
Raja Chakraverty*, Tatini Debnath, Jyotirmoy Bondyopadhyay
The most common form of Female Sexual Dysfunction (FSD), known as Hypoactive Sexual Desire Disorder (HSDD), is exhibited in a variety of ways. According to certain ideas, HSDD is related to neurotransmitter abnormalities of a neurological component. One of the innovations in established psychological techniques was the "off-label" use of dopaminergic substances like bupropion and testosterone. Before the FDA approved the drug flibanserin to treat the disorder, no treatments were available. Based on its antagonistic tendency to serotonin specifically created for HSDD treatment, flibanserin has gained acceptability as a nonhormonal alternative. Its use has shown some observable effects, including elevated sexual drive scores and fulfilling sexual experiences. Additionally, flibanserin has lessened FSD-related distress in premenopausal women with HSDD diagnoses as well as in a small postmenopausal group. Similar to other CNS medications, flibanserin can cause nausea, dizziness, drowsiness and in rare instances, syncope. Despite disagreements regarding its approval as an HSDD treatment, flibanserin unmistakably offers relief to FSDafflicted women and is a crucial addition to promoting women's health.
Published Date: 2025-03-20; Received Date: 2024-04-30